In 2012, the first PrEP (pre-exposure prophylaxis) drugs came onto the market, poised to revolutionize the field of HIV prevention. ‘The Pill’ promised to usher in a kind of sexual revolution, particularly for gay men and trans women. Sexual rights activists and health workers around the world analogized PrEP to birth control, suggesting that PrEP would allow particular sexual minority populations to secure bodily autonomy and serve as a tool for the self-management and mitigation of risk. (read more...)